课题基金 / 基金详情

HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS

HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
多发性硬化症急性加重中的 HU23F2G
批准号：
6281706
负责人：
Jerry Saul Wolinsky
金额：
$1.36万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281706
关键词：
clinical research drug screening /evaluation hormone therapy human subject human therapy evaluation immunotherapy methylprednisolone monoclonal antibody multiple sclerosis

项目摘要

项目成果

Jerry Saul Wolinsky的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The study is designed to evaluate the efficacy & safety of Hu23F2G administered intravenously to patients with acute exacerbations of multiple sclerosis (MS) as compared to placebo and corticosteroid treatment. Hu23F2G is a humanized anti-CD18 monoclonal antibody which has been effective in a non-human primate experimental model of MS. This is a Phase 2 study in which patients will be randomized to treatment for 3 days with placebo, methylprednisoline, or Hu23F2G at 1 or 2 mg/kg. Subjects will be followed for 1 year after treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
COPAXONE IN PATIENTS WITH MULTIPLE SCLEROSIS--OPEN LABEL STUDY